MedTrace Logo

A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

NCT06582264 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2026-02-17

No results posted yet for this study

Summary

A Phase 1b study to evaluate the safety and tolerability of MB310 given to patients who have active mild-to-moderate ulcerative colitis.

Conditions

Interventions

BIOLOGICAL

MB310

Live bacterial therapeutic for oral administration

OTHER

Placebo

MB310-matching placebo for oral administration

DRUG

Vancomycin

Antibiotic

Sponsors & Collaborators

  • Microbiotica Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-27
Primary Completion
2026-01-08
Completion
2026-01-08

Countries

  • Austria
  • Bulgaria
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06582264 on ClinicalTrials.gov